Trial Profile

A PHASE 3 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BEROTRALSTAT PROPHYLAXIS IN CHILDREN WITH HEREDITARY ANGIOEDEMA WHO ARE 2 TO < 12 YEARS OF AGE

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jul 2025 According to a BioCryst Pharmaceuticals media release, results from interim analysis of this study will be presented in a poster at at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025.
16 Jun 2025 Interim Results presented in the BioCryst Pharmaceuticals Media Release.
16 Jun 2025 According to a BioCryst Pharmaceuticals media release, result data from this study were presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasgow, United Kingdom, from June 13 to 16, 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com